Is Omkar Pharmachem overvalued or undervalued?

As of 12 May 2025, the valuation grade for Omkar Pharmachem has moved from risky to very expensive, indicating a significant shift in its market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 27.97, an EV to EBITDA of 28.20, and a PEG ratio of 5.31, all of which suggest that the stock is trading at a premium compared to its earnings growth potential. In comparison to its peers, Omkar Pharmachem's valuation metrics are notably higher than those of companies like Cipla, which has a PE ratio of 22.99 and an EV to EBITDA of 15.93, and Dr. Reddy's Labs, with a PE ratio of 19.49 and an EV to EBITDA of 12.87. This further reinforces the view that Omkar Pharmachem is overvalued in its sector. Additionally, while the company has outperformed the Sensex over the past year with a return of 23.14% compared to 7.61%, the recent trend shows a decline in stock performance relative to the index, which may signal a correction ahead.